In order to understand the role of NF-kB in EBV transformation we have established stably transfected IkBa into lymphoblastoid cells. Two clones were obtained in which the loss of NF-kB binding activity correlated with the constitutive expression of the transgenic IkBa. Protein latency expression was determined by immunocytochemistry. Expression of surface markers, intracytoplasmic content of cytokines cell cycle analysis after BrdU incorporation and DNA staining with propidium iodide were studied by¯ow cytometry. Percentage of apoptotic cells was determined by in-situ labelling of DNA strand breaks. No signi®cative changes in EBV latency nor in cell surface marker expression was found. In contrast, intracytoplasmic TNFa levels were strongly reduced in transfected clones. Furthermore, 30% of IkBa transfected cells were apoptotic after 8 h of TNFa treatment. This correlated with a strong reduction of BrdU incorporation after 24 h of TNFa treatment. No eect was seen with non transfected cells or with cells transfected with a control plasmid. Our results suggest that the TNFa gene could be one of the targets of NF-kB in EBV infected cells and that NF-kB protects EBV-infected cells from apoptosis induced by TNFa, which may favour the proliferative eect of this cytokine.
Introduction
The Epstein Barr Virus (EBV) is able to infect and transform non tumoral B-cells in vitro and is associated with several human malignancies, such as lymphoproliferative diseases in immunocompromised patients, endemic Burkitt's lymphoma or Hodgkin's disease (see Kie and Liebowtz, 1990) . In vitro EBVtransformation of B-cells is associated with the expression of a restricted set of proteins, so-called latency proteins. Among them, the LMP1 protein has been extensively studied. After transfection, this membrane protein is able to transform cells, as well as to confer the activated phenotype of EBV-infected cells. Results from several groups demonstrated that LMP1 protein interacts directly with TRAF molecules (Mosialos et al., 1995) , which aggregation is an essential step in the transduction pathway of various member of the TNFa receptor family such as TNFa receptor types I and II, CD30, CD40. LMP1 protein induces multiple downstream eects, among which cell proliferation and activation of Rel/NF-kB proteins (Laherty et al., 1992) .
The Rel/NF-kB proteins constitute a family of ubiquitously expressed eukaryotic factors that comprises p50, p52, p65, c-Rel and RelB in mammalian cells. The members of this family are de®ned as sharing the Rel homology domain, a conserved region of approximately 300 amino acids that contains critical sequences for dimerization, DNA-binding and nuclear localization. The activity of these proteins is related to the formation of homo or heterodimers with one of the other members of the family. These proteins are involved in the positive control of the transcription of a variety of genes involved in the immune response (TNFa, interleukin 1, MHC class II, some adhesion molecules such as ICAM1. . .), the in¯ammatory response (i-NO synthase, interleukin 6 . . .) or oncogenes such as c-myc as well as some viruses such as HIV1, CMV, SV40 (see Baeuerle and Henkel, 1994; Grilli et al., 1993 for review) . The cytoplasmic localization of these proteins is due to the masking of the nuclear localization sequence by interaction with one of the IkB family inhibitors: IkBa, b, g, d and e (Verma et al., 1995 for review) . Following various cell activation events, such as B-cell receptor or T-cell receptor stimulation, exposure to certain cytokines or some viral infections, Rel/NF-kB dimers are activated. This activation corresponds to their nuclear translocation after serine phosphorylation and proteolytic degradation of IkB. In the nucleus, Rel/NF-kB heterodimers are thought to enhance the transcriptional activity of a de®ned set of genes through their binding to a`kB site', a speci®c DNA-sequence containing the consensus sequence GGGRNNYYCC.
The involvement of Rel/NF-kB dysregulation in tumorigenesis has been suggested by various reports in the literature. For example, the viral equivalent of cRel, v-Rel, which correspond to a truncated and mutated version of c-Rel, is responsible for fatal haematological diseases in chicken and turkey, and transgenic mice expressing v-Rel present rapid T-cell lymphoblastic disorders (Carrasco et al., 1996; Simek et al., 1986; Stephens et al., 1983) . One of the ®rst reports which describes the cloning of p52 correspond to the description of the Lyt-10 protein, which locus is rearranged with the t(10:14) chromosomic translocation (Neri et al., 1991) . This translocation has been reported in 14% of the Sezary T-Cell lymphoma (Migliazza et al., 1994) . Aberrant Rel/NF-kB protein expression has been reported to be associated with the malignant progression in breast cancers (Nakshatri et al., 1997; Sovak et al., 1997) . Ampli®cation of the Rel locus has been reported to be a feature of primary extranodal lymphoma (Houldsworth et al., 1996) . Antisense oligonucleotides raised against the p65 mRNA inhibit the proliferation of tumoral cells whereas sense oligonucleotides favour proliferation of tumoral cells (Higgins et al., 1993) .
The fact that LMP1, the major transforming EBV latency protein, is responsible for NF-kB activation in EBV infected B-cells strongly suggests that Rel/NF-kB complexes could play a role in EBV-related lymphomagenesis. The NF-kB activation domain of LMP1 has been well de®ned, and in vitro mutations or deletions within this domain are associated with the loss of NFkB activation (Huen et al., 1995) . However, natural variants of LMP1 from EBV isolates still have the capacity to activate NF-kB, even if mutations or deletions are occurring within the NF-kB activation domain, suggesting that it exerts a selective pressure on EBV strains to keep intact the capacity of NF-kB activation through the LMP1 proteins in EBV-infected B-cells (Rothenberger et al., 1997) . LMP1 activation of NF-kB corresponds to the translocation of p65/p50 complexes in the nucleus, and targets IkBa phosphorylation and degradation, and over-expression of IkBa inhibits the NF-kB activation by LMP1 (Herrero et al., 1995) . Therefore, IkBa expressing vectors could be an interesting tool in controlling NF-kB activity and thus, to understand the relationships between EBV-induced transformation and NF-kB activation.
In order to understand the role of Rel/NF-kB proteins in EBV-related lymphomagenesis, we have stably transfected the IkBa cDNA, mutated on serine 32 and 36, which blocks its degradation in a lymphoblastoid cell line (LCL). This mutated IkBa is no longer degraded in response to activating signals. We have obtained two clones in which expression of the transgene was correlated with the loss of NF-kB binding activity. We have analysed the EBV latency, surface phenotype, intracytoplasmic cytokine content, cellular proliferation and apoptosis. We show that intracytoplasmic levels of TNFa in IkBa transfected clones were reduced to the level of EBV negative B cell lines. Moreover, TNFa induced both cell apoptosis and cell proliferation arrest in IkBa transfected cell.
Results

Establishment of stably transfected lymphoblastoid cells with the mutated IkBa cDNA
In agreement with previous reports, preliminary experiments showed that all EBV positive lymphoblastoid cell lines had a constitutive NF-kB binding activity. This NF-kB was not enhanced after treatment of cells with PMA plus ionomycin, although this treatment was ecient on NF-kB induction in EBV(7) Burkitt cell lines (not shown). Supershift experiments showed the presence of p65/p50 and p50 2 complexes (Figure 1a) . We have transfected the pcDNA3 vector containing the mutated cDNA of IkBa under the control of CMV promoter, into lymphoblastoid cells. Mutations consist in substitution of the two serine 32 and 36 by alanines (IkBa 32/36A ) (Traenckner et al., 1995) . Control transfection experiments were performed in parallel with the empty plasmid. Thirty-®ve clones out of 576 ensemenced wells were growing in selective medium. Clones were screened for both the loss of NF-kB binding activity by EMSA and genomic integration of IkBa 32/36A cDNA by Southern blot. Three clones 9C4, 9B8 and X9 showed a genomic integration of IkBa 32/36A cDNA (not shown). Among them, the 9C4 clone still had constitutive nuclear NF-kB binding activity (see Figure 1b) . Constitutive NF-kB binding activity was almost abolished in 9B8 clone and totally abolished in X9 clone (Figure 1b) . Treatment of cells with PMA plus ionomycin failed to induce a nuclear NF-kB binding activity in X9 clone and induced a hardly visible signal in 9B8 clone. Analysis of the expression of the IkBa 32/36A protein was done by Western blot. The wild type and the IkBa 32/36A are distinguishable on the basis of their electrophoretic migration because the IkBa 32/36A migrates slightly slower in SDS gels (Traenckner et al., 1995) . Control experiments indicating the position of the IkBa 32/36A protein were done using a clone previously described by HPB-ALL T-lymphoblast cell line stably transfected with IkBa 32/36A (Ferreira et al., 1998) . Results showed that IkBa 32/36A was not detected in the 9C4 clone, was weakly expressed in 9B8 clone and strongly expressed in X9 clone (Figure 1c) . Therefore, the study was continued with both 9B8 and X9 clones. Note that endogenous IkBa was strongly expressed in both transfected and non transfected cells, suggesting that in spite of the continuous NF-kB activation, IkBa is permanently resynthesized in EBV infected cells.
Phenotypic analysis of IkBa transfected clones
We ®rst characterized the surface phenotype of IkBa 32/36A stably transfected clones. Our results did not evidence any signi®cant modi®cation in expression of adhesion molecules (CD11a, CD18, CD44, CD58), molecules having a kB site in their promoter region (CD25, CD48, CD54, HLA class I and II molecules) nor in activation markers (CD23, CD30, CD39, CD71). LMP1, EBNA2 and BZLF1 protein expression was unaected in transfected clones as assessed by immunocytochemistry (not shown).
We next looked after the synthesis of three cytokines, IL-2. IL-6, and TNFa that are potentially regulated by NF-kB and could play a role in B-cell proliferation. As control, we have tested the IL-10 expression on transfected cells because its expression has never been reported so far to be NF-kB dependent. Moreover, we have evaluated the synthesis of these cytokines in both Burkitt EBV (7) and EBV(+) cell lines. After incubation of cells with brefeldin A, which prevents cytokine secretion by allowing its accumulation in the cytoplasm, and intracytoplasmic labelling, synthesis of cytokines was estimated by¯ow cytometry (Picker et al., 1995) . As expected (Klein et al., 1996) , we have found highest levels of IL10 in LCL cells and intermediate levels of IL10 in Burkitt EBV(+) cells (Figure 2 ). Intracytoplasmic levels of IL10 were similar in IkBa transfected cells and non transfected cells (Figure 2 ). IL-2 and IL-6 intracytoplasmic levels were heterogeneous from one cell to the other. Levels of these cytokines were not aected by IkBa transfection in LCL cells (not shown). TNFa was detected in cytoplasm of both EBV(7) and EBV(+) cells. However,¯uorescence intensity of intracytoplasmic labelling of TNFa in EBV(+) cells was fourfold higher than in EBV(7) cells ( Figure 3a) . The comparison of TNFa intracytoplasmic labelling in both Burkitt EBV7 and EBV+ cells suggested that EBV infection of Burkitt cells is associated with a strong increase of TNFa synthesis ( Figure 3a) . TNFa intracytoplasmic levels were strongly reduced in both 9B8 and X9 IkBa transfected clones (Figure 3b ). Overlapping of¯uorescence graphs of TNFa levels in X9 clone and EBV(7) Burkitt cells showed that TNFa synthesis levels in IkBa transfected clones reached down those of EBV (7) cells (Figure 3c ). These results showed that the loss of NF-kB binding activity in LCL cells was associated with a decrease of TNFa synthesis, reaching levels similar to those found in EBV7 cells. Therefore, this result suggested that the NF-kB constitutive activity could be responsible for a continuous over-synthesis of TNFa in EBV infected cells. Analysis of proliferation and apoptosis of IkBa 32/36A transfected clones It has been reported that NF-kB activation by TNFa protects cell from TNFa induced apoptosis (Beg and Baltimore, 1996; Van Antwerp et al., 1996; Wang et al., 1996) . Thus we have investigated the eect of TNFa on cell cycle. Cells were ®rst incubated for 24 h with 10 ng/ml of TNFa and then BrdU incorporation was performed during 4 h and cell cycle analysis was performed with a¯ow cytometer after DNA staining with propidium iodide (Lowe et al., 1993) . Results are presented in Figure 4 . No eect of TNFa treatment was seen on non transfected cells or cells transfected with the control plasmid. By contrast, the number of BrdU positive cells was strongly decreased in both X9 and 9B8 clones after TNFa treatment. The percentage of apoptotic cells on the X9 clone was ®rst estimated morphologically after May GruÈ nwald Giemsa staining and con®rmed using a test which evidenced the DNA strand breaks ( Figure 5 ). Results showed that TNFa treatment induced apoptosis in IkBa transfected cells but not in non transfected cells ( Figure 5 ) or cells transfected with the control plasmid (not shown). These results suggested that the loss of NF-kB constitutive activity favoured the TNFa transduction pathway leading to apoptosis in EBV(+) cells.
Discussion
LMP1 is inducing a continuous NF-kB activation. A recent report suggested natural deletion variants of LMP1 are submitted to a selection pressure resulting in intact NF-kB activation capacities (Rothenberger et al., 1997) . This raises the question of the role of NF-kB in EBV-related lymphomagenesis. In order to answer this question we have inhibited NF-kB activity by transfecting the inhibitor IkBa in LCL cells. Our results showed that the loss of nuclear NF-kB activity was associated with the decrease of TNFa synthesis and the increase of sensitivity to apoptosis after TNFa treatment.
A constitutive NF-kB binding activity was found in our EBV positive lymphoblastoid cells, as described previously (Laherty et al., 1992) . Supershift experiment evidenced both p65/p50 and p50 2 complexes (Figure 1) , which is consistent with previous reports (Herrero et al., 1995) . No NF-kB binding activity was detected in IkBa transfected clones, which indicated that both p65/ p50 and p50 2 complexes were apparently inhibited by IkBa. IkBa has been shown ®rst to target p65 containing dimers, whereas no inhibitory eect was seen on the binding of p50 2 dimers (Baeuerle and Baltimore, 1989) . However, characterization of interactions between IkBa and p50 or p65 showed that, in vitro, IkBa may weakly interact with p50 2 homodimers and partly inhibit its binding activity (Liou et al., 1992) . Moreover, transfection of IkBa has been shown to induce a relocalization of p50 into the cytoplasm (Zabel et al., 1993) . Finally, p105 gene expression is regulated by NF-kB (Ten et al., 1992) and LMP1 induces p105 through NF-kB activation (Herrero et al., 1995) . Since our EMSA experiments were done on nuclear extracts, the lack of detection of any Rel/NFkB complexes in our transfected clones may be explained by three hypothesis which are not exclusive: (i) IkBa may translocate in the nucleus (ArenzanaSeisdedos et al., 1995; Cressman and Taub, 1993; Zabel et al., 1993) where it inhibits the DNA binding of Rel/ NF-kB complexes with an ecacy related to its dierential anity to these complexes; (ii) IkBa may relocate Rel/NF-kB complexes into the cytoplasm, including p50 2 complexes and (iii) the constitutive expression of the stably transfected mutated IkBa 32/36A may down regulate the p105 gene transcription leading to a decrease in the total amount of some Rel/NF-kB proteins such as p50.
Except for TNFa, we did not evidence signi®cative changes in expression of various genes that could be theoretically regulated by NF-kB complexes such as CD25, CD48, CD54, HLA class I and II molecules or IL-1, 2 or 6. This could be due to a weak in vivo NF-kB dependence of genes analysed in EBV infected B cells. Alternatively, it could re¯ect a mechanism by which EBV infected cells escape from the control of gene expression by cellular factors. One interesting example is related to the IL-6 gene regulation and its relationships with NFkB and EBNA2. Regulation of IL-6 may involve NF-kB (Libermann and Baltimore, 1990). However, IL-6 gene transcription could potentially become NF-kB independent in EBV infected cells because of interference between EBNA2 and kB sites. EBNA2 targets the RBP-Jk cellular factor (Grossman et al., 1994; Henkel et al., 1994; Zimber-Strobl et al., 1994) . RBP-Jk is involved in negative regulation of genes (Hsieh and Hayward, 1995; Waltzer et al., 1995) . Binding of EBNA2 to RBP-Jk leads to the formation of a complex which activates gene transcription through the transcriptional domain of EBNA2. This complex is able to activate the transcription of numerous cellular genes such as CD23 as well as in the LMP1 gene of the EBV episome (Grossman et al., 1994; Henkel et al., 1994; Zimber-Strobl et al., 1994) . A recent report showed that RBP-Jk is also able to bind to the kB site of the IL-6 gene and is responsible for low basal levels of IL-6 gene transcription in ®broblastic cells (Plaisance et al., 1997) . Thus, in EBV-infected cells, EBNA2 could target the RBP-Jk bound to the kB site of the IL-6 gene, leading to its over-transcription in an NFkB independent manner (Plaisance et al., 1997) . This example shows the possibility for EBV to render transcription of some kB-regulated genes independent of NF-kB activation even if NF-kB is continuously activated by EBV.
We found a correlation between a decrease of TNFa synthesis and the loss of NF-kB binding activity in our IkBa transfected clones. One of the ®rst reports on the regulation of the TNFa gene transcription evidenced the presence of kB sites in its promoter region and showed that this kB transcriptional activity is correlated with a constitutive NF-kB binding activity in macrophages Shakhov et al., 1990) . Three kB sites have been found in the promoter region of the human TNFa gene (Goldfeld et al., 1991) . These kB sites are able to bind NF-kB complexes. But, little or no eect has been observed on the induction of transcriptional activity through the TNFa promoter when kB sites are deleted. In fact, the activity of the kB sites of the TNFa promoter depends on the cell type. These kB sites are inactive in T-cells (Goldfeld et al., 1991) . However, multimerization of the kB sites of the TNFa promoter region is able to confer an inducible transcriptional activity of a reporter gene after PMA stimulation in the
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Raji cell line (an EBV positive Burkitt cell line) (Goldfeld et al., 1991) . Our results showed that, in IkBa transfected cells, the loss of NF-kB activity was associated with a dramatic decrease of TNFa synthesis reaching TNFa levels in EBV negative Burkitt cells. Two reports evidenced relationships between the loss of NF-kB activity and the decrease of TNFa gene expression. Both were using the pharmacological property of Aspirin which is to inhibit NF-kB by stabilizing IkBa. Both reports showed that TNFa gene transcription is NF-kB dependent in macrophages (Osnes et al., 1996; Shackelford et al., 1997) . Another report showed that levels of TNFa synthesis are correlated with levels of NF-kB binding activity in human B-cells (Coral et al., 1997) . Finally, Aspirin blocks EBV-induced B-cell proliferation in vitro (Sugano et al., 1997) . Together with our results, this strongly suggests that the TNFa gene could be a genuine target of Rel/NF-kB complexes in some de®ned cell types such as macrophages and B-cells and that continuous NF-kB activation in EBV-infected B-cells by LMP1 is responsible for a continuous over-expression of the TNFa gene. Constitutive NF-kB binding activity was hardly detectable in EBV negative Burkitt cells (not shown). However, after brefeldin A incubation of these cells (which blocks the cytokine secretion), accumulation of TNFa protein was still detectable in both IkBa transfected clones and EBV negatives Burkitt-cells, suggesting that other components of the TNFa regulatory region are also playing important roles in the transcription of the TNFa gene. Indeed, TNFa gene expression may be NF-kB independent in mice cells treated with LPS (Goldfeld et al., 1990) or in human pernicious malaria (McGuire et al., 1994) . Nevertheless, our results suggest that Rel/NF-kB complexes could play a role in over-expression of TNFa gene in EBV-infected B-cells.
The role of NF-kB complexes in TNFa signalling seems to be at least to protect cells from apoptosis induced by the same TNFa (Beg and Baltimore, 1996; Van Antwerp et al., 1996; Wang et al., 1996) . Our results showed that the loss of NF-kB binding activity in EBV infected cells made them sensitive to TNFainduced apoptosis. LMP1 protein is mimicking the TNFRII activation cascade by aggregating TRAF2 molecules, leading to NF-kB activation and cell proliferation (Kaye et al., 1996) . Our results suggest that TNFa gene could be a target of NF-kB in EBVinfected cells. Therefore, it seems likely that continuous NF-kB activation in EBV-infected cells would protect cells from adverse cytotoxic eects of autocrine TNFa secretion, and favour cell proliferation induced by permanent TRAF2 molecule cascade activation.
Roles of TNFa in lymphomagenesis are highly suspected by the fact that high levels of TNFa in plasma of patients having non Hodgkin's lymphomas is predictive of a poor prognosis (Macia et al., 1996; Salles et al., 1996; Warzocha et al., 1997a,b) . The proliferative eect of TNFa on B-cells is well known (Cordingley et al., 1988; Jelinek and Lipsky, 1987; Kehrl et al., 1987) . In vitro, EBV infection is associated with TNFa secretion (Jochems et al., 1991; Klein et al., 1996; Sung et al., 1988) . Our results suggest that TNFa could be a target gene of NF-kB in EBV-infected cells. By protecting cells against TNFa-induced apoptosis, continuous NF-kB activation may therefore favour a synergy between EBV and TNFa in B-cell proliferation.
Materials and methods
Cells
Two EBV-Burkitt cell lines (Iarc/BL31 from Pr Lenoir, CIRC, Lyon, France, and DG75), three EBV+ Burkitt cell lines (34831 and Iarc/BL36 from Pr Lenoir and RAJI) and ®ve EBV lymphoblastoid cell lines (ARB, PRI from Dr F Praz, IOCMH, Bobigny, France and 1462, F263 and 10847 from Pr Lenoir) were cultured continuously in RPMI 1640 with standard concentration of L-glutamine, antibiotics and 10% foetal calf serum. The A3 clone described previously (Ferreira et al., 1998) and corresponds to HPB-ALL parental cells stably transfected cells with the IkBa 32/36A cDNA.
Plasmid constructs
The plasmid construct pCMV-IkBa 32/36A has been described by Zabel et al. (1993) , modi®ed by Traenkner et al. (1995) and is a kind gift of PA Baeuerle. It consists in IkBa cDNA, in which serines at position 32 and 36 were substituted by alanines, cloned the pcDNA3 vector from Invitrogen. Control plasmid consists in the empty plasmid pcDNA3. PGL2-Luc plasmid was purchased from Promega (Lyon, France).
Transfection and cloning of cells
Since LCLs are known to be refractory to stable transfection, a preliminary step has consisted of the analysing of cloning and transfection conditions of ®ve dierent lymphoblastoid cell lines, that were homogeneous in terms of phenotype and NF-kB constitutive activity. Transient transfection assays using the Biorad* electroporator (Biorad, Ivry/Seine, France) with the PGL2-Luc plasmid (which constitutively express the luciferase gene) allowed us to optimize the electroporation conditions, that were 250 V and 960 mF with 10 mg of plasmid per 10 million cells. Three out of the ®ve LCLs tested (PRI, F263 and 10847) appeared to be easy to transfect. Furthermore, these three LCLs were easy to clone by limiting dilution. Therefore, these three LCLs were stably transfected with the pCMV-IkBa 32/36A construct and its control, the pcDNA3 plasmid. After transfection, cells were resuspended in culture medium at 10 6 per ml and cultured 48 h without the selection antibiotic. Cells were than plated at limiting dilution on two 96 wells plates and cultured with G418 antibiotic at 0.5 mg/ml. Three series of transfection were done with both pCMV-IkBa 32/36A plasmid and the control pcDNA3, which corresponds to 576 ensemenced well. Thirty-®ve clones with pCMV-IkBa 32/36A and 30 clones with pcDNA3 were growing in selective conditions for the LCL PRI only. Southern blot using the IkBa 32/46A cDNA as a probe evidenced the integration of the transgene cDNA in three out of the 33 clones transfected with the CMVIkBa plasmid, named 9C4, 9B8 and X9.
Protein extracts and electrophoretic mobility shift assay
Nuclear and cytosolic proteins were extracted in parallel from cells as previously described (Feuillard et al., 1991) . The kB oligonucleotide was purchased from Eurogenetec (Serain, Belgium) and corresponds to the tandem kB sequence (PRE) from the HIV LTR (Korner et al., 1990; Wu et al., 1988) . Gel shift experiment were performed with 20 mg of nuclear proteins as previously described (Feuillard et al., 1991) . Supershift experiments were performed as described (Ferreira et al., 1998) and immune serum were diluted at 1/10 (immune serum no 1141 for p50, 1226 and 1207 for p65, 1136 for c-Rel, 1267 for p52 and 1319 for RelB were generously gifted by N Rice, NCI, Frederick, USA).
Western blot
Cytosolic proteins (50 mg) were fractionated on a 10% polyacrylamide gel by electrophoresis in denaturing condi-tions as previously described (Ferreira et al., 1998) . Brie¯y, after electrotransfer onto a polyvinylidene di¯uoride membrane (Millipore, Bedford, MA, USA), and membrane saturation with gelatine, incubation was done with the mouse monoclonal antibody MAD 10B (Jaray et al., 1995) , a generous gift of R Hay (University of St Andrews, St Andrews, UK) diluted at 1/400. Revelation of the antigen/ antibody complex was performed using a horseradish peroxidase-coupled anti-mouse antibody (Biorad, Ivry/ Seine, France), followed by chemiluminescent visualization (ECL system, Amersham, Buckinghamshire, UK).
Immunolabelling and phenotypic analysis
Antibodies used are listed in Table 1 . The expression of cell surface molecules was assessed by direct and indirect immuno¯uorescence staining using a Coulter XL¯ow cytometer (Coulter, Margency, France) as previously described by Feuillard et al. (1995) .
Intracytoplasmic labelling of cytokines was performed as described (Picker et al., 1995) . Brie¯y, cultured cells were incubated with Brefeldin A (Sigma, l'Isle d'Abeau Chesne, France) at 10 mg/ml for 4 h at 378C to allow intracytoplasmic accumulation of cytokines. Cells were then washed twice in PBS and ®xed in 4% paraformaldehyde 15 min at 48C in a dark room under continuous gentle stirring. After washing in PBS, cells were permeabilized using a commercial reagent containing saponin (Cytoperm B, Diaclone, BesancË on France). Each of the speci®c antibodies against cytokines were added to 10 6 cells at dilution indicated in Table 1 . Incubation was performed for 30 min at 48C in a dark room under continuous gentle stirring. Cells were washed once in PBS with 0.5% serum bovine albumin and 0.2% saponin (Sigma) and then washed once in PBS alone.
Flow cytometry analysis was done on cells gated on the basis of their forward and 908 light scatter plot and negative controls consisted in irrelevant antibodies purchased from Coulter. Latency of EBV in cells was assessed using immunocytochemistry by analysing the expression of EBNA1, EBNA2 and LMP1 molecules. Fifty thousand cells per slide were cytocentrifuged and air dried. Cells were ®xed in 4% paraformaldehyde for EBNA1 labelling and in acetone for EBNA2 and LMP1. An indirect three stage immunoperoxidase technique using the Vectastain kit (Burlingame, CA, USA) was performed according to the manufacturer's procedure. The biotinylated anti-mouse and anti-rat immune-serum were obtained from Vectastain and were used diluted at 1/150. The avidin peroxidase complex was used diluted at 1/125. Peroxidase reaction, which generates a brown labelling, was performed using di-amino-benzidine tablets (Sigma) according to the manufacturer's instructions. Counterstaining was done with Harris Haematoxilin that stains nuclei in blue. Control performed in parallel consisted of irrelevant mouse or rat monoclonal antibody.
Cell cycle analysis and apoptosis detection
Analysis of cell cycle and detection of apoptosis was done after treatment of cells with TNFa (Sigma) at 10 ng/ml. The cell cycle was analysed by¯ow cytometry after bromodeoxyuridine (BrdU) incorporation and staining of DNA with propidium iodide as described (Lowe et al., 1993) . Brie¯y, cells were incubated 4 h with BrdU (Sigma) at 10 mM. Cells were washed and ®xed in ethanol, resuspended in 2 N HCl solution with 0.2 mg/ml pepsin for 30 min. Neutralization was done with 0.1 M sodium borate. Cells were washed in PBS and resuspended in PBS plus 2% foetal calf serum and 0.5% Tween 20 (PTS). BrdU incorporated in DNA was labelled with a FITC-conjugated antiBrdU antibody (Boehringer, Meylan, France). Cells were washed in PTS and resuspended in PTS containing 0.5 mg/ml RNAse A (Quiagen, Courtaboeuf, France) and 50 mg/ml of propidium iodide (Sigma). To eliminate cell aggregates from the analysis,¯ow cytometry analysis was done on cells gated on the basis of both their forward and 908 light scatter plot and the peak and the mean of the propidium iodide¯uorescence scatter plot.
For apoptosis detection, 50 000 cells were cytocentrifuged on slides. Apoptosis of cells was ®rst recognized on the basis of cell morphology after May GruÈ nwald Giemsa staining. Apoptosis was con®rmed by detection of DNA strand breaks using the TUNEL method, according to the instructions of the manufacturer (Boehringer). Percentage of apoptotic cells was estimated under¯uorescence microscope by counting cells having DNA strand breaks. 
